RxDoctor Payments Data

Paul Sue

Pediatric Infectious Diseases · New York, NYNPI 1447571690

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,833 of the $1,927 with a category attached, or 95.1%. Every reported general payment came from a single manufacturer, Merck.

$1,927in general payments, 2019–2025

Across 8 payments — averaging $240.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$2K
$571,356in research payments, 2019–2025

Across 93 payments — averaging $6143.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$351K
  • Gilead$160K
  • Astellas Pharma Global Development$60K

What the payments were for

  • Travel & lodging$1,83395%
  • Food & beverage$955%

General payments by program year

19
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck8$1,927

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,927 in reported general payments places this provider in the 70th percentile of 73 pediatric infectious diseases providers in New York.

See all pediatric infectious diseases providers in New York

Other pediatric infectious diseases in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →